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Passive immunityHuman rhinoviruses (HRV) represent the single most important etiological agents of the common cold
and are the most frequent cause of acute respiratory infections in humans. Currently the performance
of available animal models for immunization studies using HRV challenge is very limited. The cotton
rat (Sigmodon hispidus) is a well-recognized model for the study of human respiratory viral infections.
In this work we show that, without requiring any genetic modiﬁcation of either the host or the virus,
intranasal infection of cotton rats with HRV16 resulted in measurable isolation of infective virus, lower
respiratory tract pathology, mucus production, and expression of interferon-activated genes. Intramuscu-
lar immunization with live HRV16 generated robust protective immunity that correlated with high serum
levels of neutralizing antibodies. In addition, cotton rats treated prophylactically with hyperimmune
anti-HRV16 serum were protected against HRV16 intranasal challenge. Finally, protection by immuniza-
tion was efﬁciently transferred from mothers to newborn animals resulting in a substantial reduction of
infectious virus loads in the lung following intranasal challenge. Overall, our results demonstrate that the
cotton rat provides valuable additional model development options for testing vaccines and prophylactic
therapies against rhinovirus infection.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).Introduction
Human rhinoviruses (HRV) represent the most important etio-
logical agents of common colds and the most frequent cause of
acute respiratory infections in humans [1–3]. HRV are
single-stranded positive-sense RNA viruses, members of the
Picornaviridae family, genus Enterovirus which includes the three
so far recognized species rhinovirus A, B and C and also species
enterovirus A–J [4,5]. The recent sequencing and analysis of all
known HRV serotypes classiﬁed within species A and B and of
genomic RNA corresponding to species rhinovirus C allowed a bet-
ter understanding of evolutionary relations among viruses classi-
ﬁed within the 3 species and also of some of the structural
implications of genetic variability in genes encoding capsid
proteins [6,7].HRV is currently a frequently detected virus in association with
hospitalizations for acute respiratory illness in young children and
the elderly [8,9] and also a frequent opportunistic pathogen of
transplant recipients [10]. In addition, HRV infections have been
linked to exacerbation episodes in asthmatic [11], and chronic
obstructive pulmonary disease (COPD) patients [12]. Due to the
occurrence of more than 100 HRV serotypes with extensive se-
quence variability in the antigenic sites and the lack of animal
models to test the efﬁcacy of approaches to prevent or treat infec-
tion in vivo, no rhinovirus vaccines are available for use in humans.
The lack of animal models has also limited the ability to conduct
preclinical studies of antiviral compounds.
Limitations on animal modeling options for human rhinovirus
infections are – at least in part – consequences of the high host
species speciﬁcity of these viruses. Chimpanzees have been suc-
cessfully infected with HRV14 and HRV43, and gibbons with
HRV1A, HRV2, and HRV14, but no overt illness was observed in
the infected animals [13,14]. Intracranial injections of virus into
monkeys, hamsters, or baby mice did not result in either infection
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been recently developed and utilized for the study of aspects of
minor- and major-group HRV-induced disease [17–21]. In both
mouse models HRV infection was tested showing limited replica-
tion of the virus [17]. The recent work by Edlmyer et al., McLean
et al., and Glanville et al. examined immunization of mice with re-
combinant rhinovirus capsid proteins [22–24] showing strong
serological data suggesting cross protection. However their pub-
lished data did not include proof of vaccine efﬁcacy. Thus, no suc-
cessful immunization/challenge/protection studies in any animal
model have been reported. The availability of new experimental
small animal model options is therefore still a major pressing need
in the vaccinology ﬁeld.
Over the years, the cotton rat (Sigmodon hispidus) has been
shown to support replication of a broad spectrum of human
viruses including respiratory syncytial virus (RSV) [25], non-
adapted strains of human inﬂuenza [26,27], and measles
[28,29], among others [30], providing modeling capabilities for
the corresponding infections. In the present study, we evaluated
the cotton rat as a model of human rhinovirus infection that
could potentially facilitate the development and testing of vac-
cines and prophylactic therapies aimed against these important
human viruses.Materials and methods
Virus and cells
Stocks of HRV1B (ATCC cat# VR-1645), and HRV16 (strain
11757, ATCC cat# VR-283), were produced in HeLa Ohio cells,
a generous gift of Dr. Dean Erdman (CDC, Atlanta, GA, USA).
Cells were grown in Minimal Essential Medium containing Earle
salts (E-MEM), 10% fetal bovine serum (FBS); 1.5 g/ml Na2CO3,
L-glutamine and penicillin/streptomycin and maintained in the
same medium with 2% FBS. Replication-deﬁcient virus was
generated by exposing the stock to ultraviolet light for 15 min
on ice at 100 mJ/cm2. Infectious virus titers were determined
by plaque assay under agarose overlay in monolayers of the
same cell line as described below to control for ablation of
infectivity.Animals
Four to eight weeks old cotton rats of both genders were ob-
tained from the inbred colony maintained at Sigmovir Biosystems,
Inc. (SBI). Sera from sentinel cotton rats in the colony during the
time period of all experiments tested seronegative for rhinovirus
by neutralization assay, and seronegative by ELISA to adventitious
respiratory viruses (e.g. Pneumonia Virus of Mice, Rat parvovirus,
Rat coronavirus, Sendai virus), and Mycoplasma sp. Oropharyngeal
and fecal cultures tested negative for Salmonella sp., Klebsiella sp.,
Pseudomonas sp., and Citrobacter sp.). Pups were obtained from
mothers in the same colony. Animals were housed in large polycar-
bonate cages, and fed a diet of standard rodent chow and water
ad libitum. All experiments were performed following federal
guidelines and protocols approved by SBI’s Institutional Animal
Care and Use Committee (IACUC). Cotton rats were infected
intranasally (i.n.) or immunized intramuscularly (i.m.) with
HRV16 under isoﬂurane anesthesia by application of 100 ll of
solution (106–107 PFUs) per rat. I.m. immunization with 107 PFUs
of live HRV1B, UV-inactivated HRV16 (107 PFU), or lPOL polio
vaccine was carried out under the same conditions. Serum was ob-
tained by retro-orbital blood collection under isoﬂurane anesthe-
sia. Pups (3–5 days old) were infected i.n. with 20 ll of virus(5  106 PFUs). Adult animals were euthanized by carbon dioxide
asphyxiation. Pups were euthanized by decapitation.
Virus load titration assay
Tissue samples (left lung lobe, entire nose, and trachea) from
adult animals were homogenized in 3 ml of infection medium (E-
MEM, 2% fetal calf serum, 1.5 g/ml sodium bicarbonate, 25 mM
HEPES, penicillin and streptomycin), whereas left lung lobes from
pups were homogenized in 1 ml. Infectious virus titers were deter-
mined by standard plaque assay and expressed as plaque forming
units (PFU)/g of tissue. Brieﬂy 100 ll of pure or tenfold serial dilu-
tions of tissue homogenate supernatant or virus stocks were plated
in triplicate onto conﬂuent monolayers of HeLa OH cells in 6-well
plates. After 1 h adsorption with rocking every 10 min, monolayers
were overlayed with 2 ml of 0.7% low melt agarose in E-MEM
containing 2% FBS. Following incubation for 3 days at 33 C, mono-
layers were ﬁxed with buffered formaldehyde and stained with
crystal violet.
Antibody assay
Neutralizing antibody titers were determined in a plaque-
reduction assay. Serial fourfold dilutions of serum were incubated
for 1 h at 37 C with 50 PFU of HRV16. Virus incubated with PBS
was used as control. Neutralization mixes were then plated in qua-
druplicate onto conﬂuent HeLa cell monolayers in 24-well plates,
incubated at 33 C for 1 h and overlayed with 0.7% Low Melt
Agarose in MEM. Cells were incubated at 33 C and 5% CO2 for
72 h and then ﬁxed with 1% buffered formaldehyde and stained
with crystal violet for reading.
RNA isolation and RT-PCR analysis
RNA was isolated from the lung lingular lobe using the RNeasy
Kit (Qiagen Sciences). Bronchoalveolar lavage (BAL) was collected
for total RNA isolation from a dedicated group of infected animals
by lavaging 3 times with a total 2 ml of PBS each. For mRNA assays,
cDNA was prepared by using QuantiTect Reverse Transcription Kit
(Qiagen Sciences). Each cDNA reaction was diluted to match 1 lg
of the initial RNA per 100 ll of the ﬁnal cDNA volume. Three micro-
liters of diluted cDNA were used for each qPCR reaction. A HRV16-
speciﬁc qPCR protocol was developed using primers that target the
50UTR of HRV-16 (GenBank Accession# L24917). For a quantitative
assessment of viral replication, cDNA for the negative stranded viral
RNA (as an indicator of active RNA transcription), was synthesized
by priming with 50-CCCTTTCCCAAATGTAACTTAGAAGC-30. Real-
time PCR quantiﬁcation of both strands was performed using the
forward primer 50-TCAAGCACTTCTGTTTCCCCGGT-30 and the
reverse primer 50-TCCCATCCCGCAATTGCTCATTAC-30, generating a
fragment of 370 bp. A plasmid containing the 50UTR of HRV16
was diluted to generate a copy number standard curve that allowed
for the quantiﬁcation of copies/g tissue of the negative replication
intermediates. The assessment of cotton rat Mx-1 and Mx-2 mRNA
expression was carried out as previously described [30,31].
Histopathology analysis
The right lobes of the lung were dissected with the caudal 1/3 of
the trachea attached. Lung lobes were inﬂated to their normal vol-
ume with 10% neutral buffered formalin, immersed in the same ﬁx-
ative, and then processed, parafﬁn-embedded, sectioned, and
stained with hematoxylin and eosin (H&E). Additional sections
were stained with Alcian Blue-Periodic acid-Schiff (AB-PAS) for
visualization of mucus and mucus-bearing cells. Lung sections
were evaluated for several indices of inﬂammation and cell
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compartments (described more fully in the results). Changes were
assessed subjectively and scored blindly on a 0 to 4 scale for sever-
ity (absent, minimal, mild, moderate, marked), with validation of
scoring done by two pathologists experienced in respiratory viral
pathogenesis. Graded ﬁndings included peribronchiolar inﬂamma-
tory cell inﬁltrates, bronchiolitis, bronchiolar epithelial degenera-
tion, mucous cell hyperplasia /hypertrophy, airway luminal
mucous /other exudate, perivascular inﬂammatory cell inﬁltrates,
alveolar septal inﬁltrates, and alveolar luminal inﬂammatory cell
exudates. Tracheas and nasal turbinates from selected, infected
animals were also evaluated.Statistical analysis
Viral titers, expression of Mx genes, and production of the
HRV16 replicative intermediate were calculated as geometric
means ± standard error for all animals in a group at a given timeFig. 1. Cotton rat infection with HRV16. Cotton rats were infected i.n. with 107 PFU of HR
animals at the indicated times (h) post-infection. Groups of 5–10 animals were euthaniz
infected with HRV16 compared to those of rats infected with HRV1B. Left axis shows in
times post-infection. Animals inoculated with UV-inactivated HRV16 were used as contro
HRV16-inoculated animals using logarithmic scale (n = 5 per time point). (D) One-cycle
transcripts in BAL cells from uninfected or mock-inoculated rats, and rats instilled with UV
Student t-test analysis between HRV16-infected group and each of the control groups.post infection. Student t-test was applied to determine statistically
signiﬁcant differences between two groups, using an unpaired,
two-tailed test set at p < 0.05. Pulmonary pathology scores were
expressed as the arithmetic mean ± standard error for all animals
in a group. Signiﬁcance of score differences between uninfected
and infected groups at different days post-infection for each histo-
logical parameter was analyzed by one way Kruskal–Wallis ANOVA
and set at a value of p < 0.05.Results
HRV16 infection in cotton rats
Adult cotton rats were infected i.n. with 107 PFU of HRV16.
Groups of 5 animals were euthanized at 30 min, 2, 4, 6, 8, and
10 h, and at day 1, 2, and 4 post-infection (p.i.) (Fig. 1A). Non-in-
fected animals or animals inoculated with UV-inactivated HRV16
were used as controls. Infectious HRV16 was recovered from theV16. (A) Infectious virus titers in nose, trachea, and lung homogenates from infected
ed at each time in a total of 3 independent experiments. (B) Lung viral loads in rats
put virus. (C) Quantiﬁcation of () vRNA by RT-PCR in lung tissue at the indicated
l. Insert is a blow-out of the 24 h and 48 h time points from HRV16-infected and UV-
replication of HRV16 in HeLa Ohio cells. (E) qPCR quantiﬁcation of Mx-1 and Mx-2
-inactivated HRV16 or live HRV16 at 6 h after challenge. n = 8 per group. ⁄p < 0.05 in
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No virus was detected in any of the tissues from animals eutha-
nized on day 4 p.i. or in any of the tissues from uninfected controls
(not shown). The highest virus titers were detected in the lungs
(>107 PFU/g of tissue), followed by the nose and the trachea
(106 PFU/g of tissue). A brief plateau of viral loads was detectable
in the nose and trachea between 6–10 h p.i. followed by a decrease
and clearance of virus. Infection with HRV16 at a lower dose
(106 PFU/animal) resulted in lung viral titers of 5.9  105 ± -
8.6  104 PFU/g at 8 h p.i. (n = 16), with no detectable infectious
virus at 48 h p.i. (data not shown). We compared the viral load in
the lung, between rats infected with the major group HRV16 and
rats infected with the minor group HRV1B and found that the
course of infection with the 2 viruses was very different (Fig. 1B).
Higher infectious virus titers were recovered from the lungs of ani-
mals infected with HRV16 than from animals infected with a sim-
ilar dose of hRV1B, suggesting that the cotton rat is signiﬁcantly
more permissive to infection by HRV16. Based on these results
we only used HRV16 in all the subsequent experiments.
The lung load of virus was also examined by determining pro-
duction of the replication intermediate, negative strand viral RNA
[()vRNA] by PCR (Fig. 1C). ()vRNA strand was detected in lungsFig. 2. Airway pathology in HRV16-infected cotton rats. (A) Tracheal epithelial cell defo
infected cotton rat. H&E staining, magniﬁcation 100. (B) Histopathology scores obtained
indicated days post-infection. Graphs represent the extent of peribronchiolar inﬁltration
septal inﬁltration and alveolar exudates (right). n = 3–9. ⁄p < 0.05, #p < 0.01, +p < 0.005 in
main axial airway of an uninfected (a), or a HRV16-infected animal (b). (D) Scores for m
ANOVA.of infected animals up to 48 h p.i. (Fig. 1C, see also inset). Animals
inoculated with UV-inactivated HRV16 (107 PFU) showed unde-
tectable negative strand HRV-16 RNA. The apparent rapid kinetics
of viral replication observed in vivowere consistent with data from
one-step growth curves carried out in HeLa Ohio cells showing that
a complete replication cycle of HRV16 occurs in 6–10 h (Fig. 1D).
We measured the expression of cotton rat Mx1 and Mx-2 genes
in the lungs in response to HRV16 infection as evidence of presence
of type I IFNs. Mx1 and Mx2 are two IFN-inducible genes that
mediate antiviral activity [31–33]. The activation of expression of
Mx-1 and Mx-2 was detected in BAL cells of HRV16-infected cotton
rats at 6 h p.i. (Fig. 1E) but not in either of the two subsequent time
points (12 h and 24 h – data not shown), indicating that the induc-
tion of IFN was transient.
Histopathology in HRV16-infected cotton rats
Analysis of the pathology associated with HRV16 infection was
performed in the nose, trachea, and lung. No signiﬁcant lesions
were observed in the nasal turbinate sections. Epithelial degenera-
tion was present in the trachea and large pulmonary airways of
HRV16-infected rats. Infection was associated with direct and pro-liation in HRV16-infected animals. (a) Trachea from an uninfected, or (b) HRV16-
from lungs of uninfected (uninf) or HRV16-infected animals and euthanized at the
, bronchiolitis, and epithelial degeneration (left); perivascular inﬁltration, alveolar
one way Kruskal–Wallis ANOVA. (C) Alcian blue-PAS staining of a bifurcation of the
ucous cell hypertrophy/hyperplasia. ⁄p < 0.05, #p < 0.01 in one way Kruskal–Wallis
Table 1
Serum neutralizing activity.
Prior exposure to HRV16a No of rats tested Percentage plaque reduction
(SE)b
1:16 1:1280
None 5 <10 <10
106 i.m 8 100 91 (9)
107 i.n. 8 25 (19) <10
a Animals exposed to HRV16 on day 0 and 21.
b Plaque reduction assay using serum obtained at day 42 post-ﬁrst exposure in
the indicated dilutions.
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that peaked on day 4 p.i. and often exposed the basal membrane
(Fig. 2A).
Lung pathology demonstrated mild but signiﬁcant alveolitis
(neutrophilic and histiocytic), and peribronchiolar inﬁltrates of
neutrophils, macrophages, and lymphocytes (Fig. 2B). Peak damage
of the lung parenchyma (perivasculitis, alveolar septal inﬁltrates,
and alveolitis) was recorded on day 1–2 p.i., whereas airway dam-
age was predominantly seen on day 3 p.i. Mucous cell hypertro-
phy/hyperplasia was evident in H&E- and AB-PAS-stained lung
sections as early as 1 day p.i. but continue elevated by day 4 p.i.
(Fig. 2C). Thus, HRV16 infection in the cotton rat reproduces as-
pects of human disease in the URT with detectable inﬂammation
in the lower airways and lung parenchyma. In contrast, infection
with HRV1B did not result in signiﬁcant pathology.Fig. 3. Immunogenicity and efﬁcacy of immunization with live HRV16. (A) Viral titers in
post i.m. injection of PBS, post i.n. infection with 107 PFUs of HRV16, or post i.m. immu
between HRV16-i.n. immunized group and the PBS-injected control group. (B) Immuniza
speciﬁc for HRV16 and the intramuscular route. (C) Neutralization of viral infection occ
(neutralization titers > 1280), subsequently challenged and sacriﬁced 10 h after challenge
also sacriﬁced 10 h p.i. Mixed homogenates in the indicated dilution (immune:control
performed by diluting a control homogenate with titration media. The reduction of result
neutralization occurring ex vivo.Antibody production in response to HRV16
Intramuscular immunization of adult rats with live HRV16 at a
dose of 106 PFUs in a priming (day 0) and boosting (day 21) sche-
dule resulted in high serum levels of neutralizing antibodies at
42 days after the ﬁrst immunization. Surprisingly, that was not
the case when the same amount of virus was instilled i.n. following
an identical schedule. As shown in Table 1, all animals immunized
intramuscularly showed neutralizing antibody titers >1280,
whereas animals that underwent i.n. infection or re-infection with
HRV16 showed low neutralizing antibody titers (<16). Further-
more, when animals were immunized i.m. once with 107 PFUs
and challenged i.n. 21 days later with HRV16 (107 PFUs), infectious
virus was not detectable in the nasal turbinates or in the trachea,
and a reduction (>3log10) in infectious virus titers was detected
in the lung (Fig. 3A). As expected, intramuscular immunization
with live HRV1B, or UV-inactivated HRV16 (107 PFU), or with a cur-
rent polio vaccine (Ipol) failed to confer measurable protection
upon i.n. HRV16 challenge (Fig. 3B).
The possibility that the observed reduction in viral titers in the
lungs of animals vaccinated i.m. was caused by neutralization
in vitro was evaluated by mixing an equal amount of HRV16-in-
fected lung homogenate from a naïve animal with lung homoge-
nates (h1, h2, h3) of individual vaccinated animals, all
euthanized at 10 h p.i. As shown in Fig. 3D, homogenate mixes
yielded the amount of virus in the lung suspension predicted from
dilution in the indicated proportions (1:2 and 1:5 respectively)
without evidence of in vitro neutralization. This result indicatedthe lung, nose, and trachea of animals challenged with HRV16 (107 PFUs) 21 days
nization with 107 PFUs HRV16. n = 5 per group. ⁄p < 0.05 in Student t-test analysis
tion with different viral preparations showed that protection by immunization was
urs in vivo. Lung homogenates from 3 animals previously immunized with HRV16
(h1, h2, h3) were mixed with homogenates of a naïve, challenged animal (PBS i.m.)
) were then titrated for determination of viral load. A control curve (media) was
ing titers in all mixes was consistent with the dilution factor and not consistent with
Table 2
Prophylactic effect of anti-HRV16 serum.
Serum
inoculated
i.p
No.
of
rats
Serum neutralizing
antibodies at the time
of challenge (geometric
mean, reciprocal ± S.E.)a
Lung titer of virus 12 h
after challenge with
107 PFU of HRV16
(geometric mean
log10 PFU/g ± S.E.)b
Control serum
(neutralizing
antibody
titer < 1:20)
10 <20 6.1 ± 0.12c,d
Immune serum
(neutralizing
antibody
titer 1:1280)
4 340 ± 96 3.9 ± 0.12c,d
(neutralizing
antibody titer
1:320)
3 104 ± 52 4.9 ± 0.22d
(neutralizing
antibody
titer 1:160)
3 55 ± 32 6.1 ± 0.23
a Measured by 60% plaque reduction assay against HRV16 and expressed as
reciprocal of the geometric mean. Serum was collected one day post-treatment.
b Measured by plaque assay.
c p<0.005.
d p<0.01.
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not to neutralization of the virus ex vivo after homogenization of
the tissue.
Passive transfer of anti-HRV16 immune serum confers protection
against HRV16 challenge
We tested the efﬁcacy of the prophylactic administration of im-
mune (neutralizing antibody titer of 1280 against HRV16) or nor-
mal cotton rat serum to protect against HRV16 challenge. The
neutralizing antibody titers detected in treated animals prior to
challenge are shown in Table 2. All animals that received 500 ll
of undiluted sera (neat) intraperitonealy or serum diluted 1:4,
24 h prior to challenge showed a reduction of lung viral titers of
2 and 1log10, respectively, whereas animals that received more di-
luted immune serum (1:8), naïve/control cotton rat serum, or PBS,
remained unprotected (Fig. 4). These data indicate that passive
transfer of antibodies can be an effective prophylactic therapy
against HRV infection.
Maternal immunization results in transfer of protection to pups
Young female cotton rats that were immunized twice i.m. with
live HRV16 (106 PFUs) were bred to unimmunized males. Newborn
pups delivered from immunized or non-immunized females (the
gestation time for S. hispidus is 4 weeks) were challenged at 3–
5 days of age with HRV16 i.n. and euthanized at 10, 24, and 48 h
p.i. Pups from non-immunized mothers showed lung HRV16 titers
consistent with those of naïve adult cotton rats challenged with
HRV16 (Fig. 5A). Pups from immunized mothers showed a statisti-
cally signiﬁcant reduction in infectious virus titers (>3log10) and
also a signiﬁcant reduction in the viral load measured as copies
of HRV16 ()vRNA (Fig. 5B). Neutralizing antibody titers in the
pups correlated with the level of lung protection. Fully protected
pups (all animals euthanized at 10 h, Fig. 5) showed neutralization
titers >8192, whereas pups euthanized at 24 or 48 h post infection
harboring low but detectable virus titers showed neutralizing anti-
body titers of 256, suggesting a correlation of protection and ser-
um neutralizing antibody titers as seen in the adults. These data
indicate that maternal immunity conferred by immunization is
transferable to newborn pups and sufﬁcient for protection of off-
spring from viral infection and possible replication in the lung.Fig. 4. Passive HRV16 antibody transfer protects animals from HRV16 challenge.
Animals were treated intraperitoneally with control cotton rat serum (anti-HRV16
neutralization titers < 20) or with different serum dilutions from animals immu-
nized i.m. with HRV16 (1  106 PFU). At 1 day post-treatment, animals were
challenged i.n. with 107 PFUs of HRV16, and euthanized 8 h later to determine lung
viral titers. Each symbol corresponds to one animal.Discussion
The morbidity and mortality attributable to rhinovirus infection
are considerable and result in billions of dollars of health care costs
every year. Despite the signiﬁcance of the problem, no effective
prevention of HRV infection or treatment of HRV-associated dis-
ease is currently available due in part to the lack of a reliable ani-
mal model suitable for protection studies.
HRV16 is one of the 91 serotypes classiﬁed within the major
group that use the well-characterized ICAM-1/CD56 receptor for
attachment and entry [34], and has been a model virus for studying
transmission of rhinoviruses [35], pathogenesis of the common
cold [35,36], virus-induced asthma and COPD [37–39], and for
the evaluation of anti-rhinovirus drugs in human volunteers be-
cause it reproducibly induces severe symptoms in human subjects.
HRV16 has been recently used for in vitro studies aiming to deﬁne
the molecular mechanisms of rhinovirus-induced inﬂammatory re-
sponses in airway epithelial cells [40,41].
Transgenic BALB/C mice expressing a human/mouse ICAM-1
chimeric receptor show human disease-relevant outcomes
including pulmonary inﬂammation and mucin production when
infected i.n. with HRV16, despite the low levels of viral replicationdetectable by RT-PCR [17]. Our data show that in contrast to the
mouse, which requires genetic manipulation, the cotton rat ap-
pears to host infection and possibly replication of HRV16 in the
URT and LRT. Although the data from examination of viral load
in the respiratory tract over time is certainly compatible with a
non-permissive model of infection and clearance of the inoculum
over time, the differences observed between the course of infection
by HRV16 and HRV1B together with the detection of ()vRNA in
infected tissues suggest that HRV16 may be actually replicating
in the cotton rat. The reﬁnement of our real time qRT-PCR proto-
cols to increase speciﬁcity for the detection of the () strand viral
RNA will provide the ability to address this important issue and
better describe the model.
In contrast to what has been described for other respiratory vir-
al infections, such as inﬂuenza [26,27], HRV infection of cotton rats
resulted only in mild epithelial damage (vacuolar degeneration,
Fig. 5. Maternal immunity confers protection to pups. (A) Newborns from naïve or HRV16-immunized females were challenged i.n. with 5  106 PFUs of HRV16 in 20 ll.
Infectious virus titers in the lung were determined by plaque assay at the indicated times p.i. (B) HRV16 () viral RNA detection in lungs of newborn cotton rats. n = 6–8
animals/group where each group consisted of pups from 2 different mothers. ⁄p < 0.05 in Student t-test comparison between group of pups whose mothers were immunized
vs groups of pups of the same age from unimmunized, naïve mothers.
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consistent with previous observations in humans [42,43].
Unlike the laboratory mouse, which either lacks or has defective
Mx genes, the cotton rat has a set of fully functional Mx genes. As
described for the human Mx counterparts [31,32,44,45], cotton rat
Mx genes are expressed in response to infection with inﬂuenza and
RSV. As shown by the present study, transient Mx gene expression
was detected in infected coton rat BAL cells 6 h post HRV16
infection. This result parallels the detection of Mx1 (MxA) and
Mx2 expression in nasal epithelial scrapings obtained 8 h after
experimental HRV16 infection of humans [46].
The results of the described experimental work show that
HRV16 infection in the cotton rat reproduces aspects of HRV-
associated human disease in the respiratory tract, causing detect-
able inﬂammation in the lower airways and lung parenchyma
and mucus production, and inducing a transient expression of
interferon-stimulated genes that merits further investigation. In
our model of i.n. infection, the pulmonary infectious viral load is
measurable within the 48 h following instillation and thus pro-
vides a powerful readout for assessment of protection by immuni-
zation and passive transfer of neutralizing antibodies. We found
that i.m. inoculation of live virus but not UV-inactivated resulted
in a signiﬁcant decrease of viral loads in nasal turbinates, trachea,
and lung of challenged animals suggesting that replication at the
site of injection played a role in the resulting. A measurable protec-
tion against challenge was achieved with only one immunization
(Fig. 3). The immunogenicity of the inoculum was likely dependent
upon viral replication in the area of immunization since UV-inacti-
vation of the virus completely abolished protection. The protection
achieved with live virus was speciﬁc for HRV16 since no protection
was conferred by immunization with live HRV1B. These results
could be due to the apparent lack of replication of HRV1B in the
cotton rat respiratory tract (data not shown), but are most likely
the result of the lack of shared neutralizing epitopes between
HRV16 and HRV1B. The spectrum of cross-reactivities of cotton
rat anti-HRV16 neutralizing antibodies should be further investi-
gated in view of the recent reports regarding the induction of
in vitro cross-neutralizing antibodies after immunization with re-
combinant HRV14 and HRV89 VP1 [22], and the weak induction
of HRV1B binding antibodies but not neutralizing antibodies in
the mouse by immunization with HRV16 VP0 [23].
Previous studies conducted in cotton rats have demonstrated
the passive transfer of maternal immunity against RSV to offspring
[47]. In this study, we showed that the anti-HRV16 immunity
elicited in mothers through i.m. immunization also conferred
complete protection of their 3–5 days old pups against i.n.challenge with HRV. Importantly, data from this experiment
strongly suggest that newborn cotton rats also support viral repli-
cation in the LRT, setting the stage for future testing of potential
antibody-based and other therapies for infants.
The cotton rat is well-recognized for its pivotal role in the
development of the immunoglobulin prophylactic treatments for
RSV-associated disease, RespiGam and Synagis [48–51]. Data
from the present study demonstrate that passive transfer of cotton
rat hyper-immune serum is also effective and that a neutralizing
antibody titer of 320 was sufﬁcient for a 2log10 reduction of viral
load in the lung. Without a doubt, the cotton rat model will be use-
ful for determining the value of different arrays of anti-rhinovirus
antibodies in an in vivo challenge experimental design.
Although the high diversity of serotypes that characterize this
group of viruses remains a major challenge for the development
of pan-crossreactive antibody-based intervention, the work con-
ducted using our cotton rat model of HRV infection generated
strong evidence that the parenteral route of immunization can be
effective and is therefore disserving of additional investigation
given the important questions that have been raised in the vacci-
nology ﬁeld regarding the design strategies that will be required
for effective multivalent HRV vaccines or therapeutic antibodies.
Importantly, our data highlight the large potential of the cotton
rat to provide an experimental platform complementary to that
offered by the available mouse models to further evaluate the
immunogenicity of individual HRV capsid proteins [22,23,47],
some of the already identiﬁed anti-HRV antibodies with docu-
mented neutralizing activities in vitro [52], antibodies targeting se-
lect domains of the virus receptor [53], as well as other alternative
antibody-based strategies under consideration [54] to support new
developments in this area.
Conclusions
In this work we show that the cotton rat hosts infection with
HRV16 with infectious virus (and negative stranded vRNA) loads
detectable in the lung of infected animals within 48 h following
intranasal infection. Infection results in measurable pathology,
mucus production, and expression of inﬂammatory mediators.
While intranasal infection with HRV16 resulted in the produc-
tion of low levels of neutralizing antibodies that conferred reduced
protection after re-challenge, intramuscular immunization with
live HRV16 resulted in strong type-speciﬁc protection that
correlated with high levels of systemic neutralizing antibodies. In
addition we demonstrated that passive transfer of antibodies
generated in vaccinated cotton rats can protect naïve animals from
J.C.G. Blanco et al. / Trials in Vaccinology 3 (2014) 52–60 59pulmonary infection. Thus, these results demonstrate that the cot-
ton rat is a suitable animal model for challenge studies to explore
the development of anti-rhinovirus vaccines and anti-viral
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